论文部分内容阅读
目的：探讨文拉法辛联合丁螺环酮治疗难治性抑郁症的临床疗效和安全性。方法将60例难治性抑郁症患者随机分为两组，均口服文拉法辛治疗，联合组联合丁螺环酮治疗，观察4周。于治疗前后采用汉密顿抑郁量表评定临床疗效，副反应量表评定不良反应。结果治疗4周末联合组显效率为77．4％、有效率为87．1％，对照组分别为42．5％、85．0％，联合组显效率、有效率显著高于对照组（χ2＝13．02、5．01，P＜0．05或0．01）。两组不良反应较轻微，主要表现为恶心、出汗、头疼等。结论文拉法辛联合丁螺环酮治疗难治性抑郁症具有增效作用，疗效显著，起效快，不增加不良反应，显著优于单用文拉法辛治疗。“,”Objective To explore the efficacy and safety of venlafaxine combined with buspirone in the treatment of treatment‐resistant depression (TRD) .Methods Sixty TRD patients were randomly divided into two groups both taking orally venlafaxine ,combination group was plus buspi‐rone for 4 weeks .Efficacies were assessed with the Hamilton Depression Scale (HAMD) before and after treatment and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results At the end of the 4th week obvious effective and effective rate were respectively 77 .4% and 87 .1% in combination group and 42 .5% and 85 .0% in control group ,the former was significantly higher than the latter (χ2 =13 .02 ,5 .01 ;P<0 .05 or 0 .01) .Adverse reactions of both groups were mild and mainly nausea ,diaphore‐sis ,headache and so on .Conclusion Venlafaxine combined with buspirone has a synergism and an evident effect ,takes effect more rapidly ,and doesn’t increase adverse reactions compared with single venlafaxine in the treatment of treatment‐resistant depression .